News | September 12, 2023
Indian pharma industry to witness 8-10% revenue growth in fiscal 2024: CRISIL
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Price was the key driver for the period
Subscribe To Our Newsletter & Stay Updated
